225 related articles for article (PubMed ID: 38238949)
21. Comparative study on the efficacy and safety of transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for large unresectable hepatocellular carcinoma.
Yang J; Shang X; Li J; Wei N
J Gastrointest Oncol; 2024 Feb; 15(1):346-355. PubMed ID: 38482220
[TBL] [Abstract][Full Text] [Related]
22. Pseudo-capsulated Hepatocellular Carcinoma: Hepatic Arterial Infusion Chemotherapy Versus Transcatheter Arterial Chemoembolization.
An C; Yao W; Zuo M; Li W; Chen Q; Wu P
Acad Radiol; 2024 Mar; 31(3):833-843. PubMed ID: 37487879
[TBL] [Abstract][Full Text] [Related]
23. ALBI and P-ALBI grade in Child-Pugh A patients treated with drug eluting embolic chemoembolization for hepatocellular carcinoma.
Carling U; Røsok B; Line PD; Dorenberg EJ
Acta Radiol; 2019 Jun; 60(6):702-709. PubMed ID: 30205701
[TBL] [Abstract][Full Text] [Related]
24. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization.
Hatooka M; Kawaoka T; Aikata H; Morio K; Kobayashi T; Hiramatsu A; Imamura M; Kawakami Y; Murakami E; Waki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Chayama K
Anticancer Res; 2016 Jul; 36(7):3523-9. PubMed ID: 27354618
[TBL] [Abstract][Full Text] [Related]
25. Impact of Transarterial Chemoembolization or Hepatic Artery Infusion Chemotherapy on Liver Function after Hepatocellular Carcinoma Resection: An Observational Study.
Yue R; Liu X
Digestion; 2023; 104(4):291-298. PubMed ID: 36746122
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma.
Ando Y; Kawaoka T; Amioka K; Naruto K; Ogawa Y; Yoshikawa Y; Kikukawa C; Kosaka Y; Uchikawa S; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Fukuhara T; Mori N; Takaki S; Tsuji K; Nonaka M; Hyogo H; Aisaka Y; Masaki K; Honda Y; Moriya T; Naeshiro N; Takahashi S; Imamura M; Chayama K; Aikata H
Oncology; 2021; 99(8):507-517. PubMed ID: 33946070
[TBL] [Abstract][Full Text] [Related]
27. The safety and efficacy of balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma refractory to conventional transcatheter arterial chemoembolization.
Kim PH; Gwon DI; Kim JW; Chu HH; Kim JH
Eur Radiol; 2020 Oct; 30(10):5650-5662. PubMed ID: 32409860
[TBL] [Abstract][Full Text] [Related]
28. Safety evaluation of combination treatment of drug-eluting bead transarterial chemoembolization and immune checkpoint inhibitors for hepatocellular carcinoma: An increased risk of liver abscess with treatment interval less than one month.
Chiu SH; Lin HH; Feng AC; Lo CH; Hsieh CB; Chen PK; Chang WC
Eur J Radiol; 2024 Jan; 170():111266. PubMed ID: 38185027
[TBL] [Abstract][Full Text] [Related]
29. History of Transcatheter Arterial Chemoembolization Predicts the Efficacy of Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma Patients.
Onishi H; Nouso K; Takaki A; Oyama A; Adachi T; Wada N; Takeuchi Y; Shiraha H; Okada H
Acta Med Okayama; 2022 Dec; 76(6):695-703. PubMed ID: 36549772
[TBL] [Abstract][Full Text] [Related]
30. Chemoembolization alone vs combined chemoembolization and hepatic arterial infusion chemotherapy in inoperable hepatocellular carcinoma patients.
Gao S; Zhang PJ; Guo JH; Chen H; Xu HF; Liu P; Yang RJ; Zhu X
World J Gastroenterol; 2015 Sep; 21(36):10443-52. PubMed ID: 26420971
[TBL] [Abstract][Full Text] [Related]
31. Hepatic Arterial Infusion Chemotherapy with Oxaliplatin Plus Raltitrexed as an Alternative Option in Advanced Hepatocellular Carcinoma Patients with Failure of, or Unsuitability for, Transarterial Chemoembolization.
Wu Y; Zheng S; Zhang Z; Chen G; Chen X; Zheng T; Guo X; Chen H; Wang M; Xie X; Zhang B
Medicina (Kaunas); 2022 Sep; 58(10):. PubMed ID: 36295504
[No Abstract] [Full Text] [Related]
32. Transarterial chemoembolization with hepatic arterial infusion chemotherapy plus S-1 for hepatocellular carcinoma.
Guo JH; Liu SX; Gao S; Kou FX; Zhang X; Wu D; Li XT; Chen H; Wang XD; Liu P; Zhang PJ; Xu HF; Cao G; Zhu LZ; Yang RJ; Zhu X
World J Gastroenterol; 2020 Jul; 26(27):3975-3988. PubMed ID: 32774071
[TBL] [Abstract][Full Text] [Related]
33. Comparison Between Portal Vein Perfusion Chemotherapy and Neoadjuvant Hepatic Arterial Infusion Chemotherapy for Resectable Intermediate to Advanced Stage Hepatocellular Carcinoma.
Pan Y; Mei J; Chen J; Zhang D; Wang J; Wang X; Yi M; Zhou Z; Zhang Y; Chen M; Guo R; Xu L
Ann Surg Oncol; 2022 Mar; 29(3):2016-2029. PubMed ID: 34637058
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of hepatic arterial infusion chemotherapy combined with immune checkpoint inhibitors and tyrosine kinase inhibitors in advanced hepatocellular carcinoma: A systematic review and meta‑analysis.
Li Z; Xu Y; Qu W; Liu P; Zhu Y; Li H; Guo Y; Liu X
Oncol Lett; 2023 Dec; 26(6):534. PubMed ID: 38020293
[TBL] [Abstract][Full Text] [Related]
35. A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma.
Kim HY; Kim JD; Bae SH; Park JY; Han KH; Woo HY; Choi JY; Yoon SK; Jang BK; Hwang JS; Kim SG; Kim YS; Seo YS; Yim HJ; Um SH;
Korean J Hepatol; 2010 Dec; 16(4):355-61. PubMed ID: 21415578
[TBL] [Abstract][Full Text] [Related]
36. Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma.
Liu BJ; Gao S; Zhu X; Guo JH; Zhang X; Chen H; Wang XD; Yang RJ
World J Gastrointest Oncol; 2020 Jun; 12(6):663-676. PubMed ID: 32699581
[TBL] [Abstract][Full Text] [Related]
37. Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.
Kawaoka T; Aikata H; Hyogo H; Morio R; Morio K; Hatooka M; Fukuhara T; Kobayashi T; Naeshiro N; Miyaki D; Hiramatsu A; Imamura M; Kawakami Y; Takahashi S; Waki K; Tsuji K; Kohno H; Kohno H; Moriya T; Chayama K
J Dig Dis; 2015 Sep; 16(9):505-12. PubMed ID: 26121102
[TBL] [Abstract][Full Text] [Related]
38. Clinical outcomes of hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and anti-PD-1 immunotherapy for unresectable intrahepatic cholangiocarcinoma.
Zhang N; Yu BR; Wang YX; Zhao YM; Zhou JM; Wang M; Wang LR; Lin ZH; Zhang T; Wang L
J Dig Dis; 2022 Aug; 23(8-9):535-545. PubMed ID: 36148493
[TBL] [Abstract][Full Text] [Related]
39. Comparison of Modified Child-pugh (MCP), Albumin-bilirubin (ALBI), and Child-pugh (CP) score for predicting of survival in Hepatocellular Carcinoma Patients Treated with Transcatheter Arterial Chemoembolization.
Liu Y; Cheng C; Zhou H; Hu S; Wang H; Xie Q; Lei L; Wang P; Liu G; Hu H
Bull Cancer; 2021 Oct; 108(10):931-939. PubMed ID: 34247763
[TBL] [Abstract][Full Text] [Related]
40. Comparison of different adjuvant therapy regimen efficacies in patients with high risk of recurrence after radical resection of hepatocellular carcinoma.
Feng X; Feng GY; Tao J; Ao YP; Wu XH; Qi SG; Shi ZR
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10505-10518. PubMed ID: 37284841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]